



## Palliative and End-of-Life Measure Evaluation Recusals

The [NQF CDP Conflict of Interest Policy](#) requires that Committee members identified as having a potential conflict of interest in relation to specific measures must recuse themselves from evaluation and voting on those measures when seated on the Committee.

In the review of disclosure of interests submitted by Committee members, NQF is requiring the following recusals be made during the measure evaluation period.

### *Measures Under Review & Committee Member Recusal*

Measure Number	Measure Title	Measure Steward	Committee Member Recusals
1641	Hospice and Palliative Care – Treatment Preferences	University of North Carolina – Chapel Hill	<ul style="list-style-type: none"><li>Christine Seel Ritchie MD, MSPH Professor of Medicine in Residence, Harrison Fishbon Distinguished Professor for Clinical Translational Research in Aging, University of California, San Francisco, Jewish Home of San Francisco Center for Research on Aging</li></ul>



0216	Proportion of patients who died from cancer admitted to hospice for less than 3 days	American Society of Clinical Oncology	<ul style="list-style-type: none"> <li>Christine Seel Ritchie MD, MSPH Professor of Medicine in Residence, Harrison Fishbon Distinguished Professor for Clinical Translational Research in Aging, University of California, San Francisco, Jewish Home of San Francisco Center for Research on Aging</li> <li>Amy J. Berman, BSN Senior Program Officer, John A. Hartford Foundation</li> </ul>
0215	Proportion of patients who died from cancer not admitted to hospice	American Society of Clinical Oncology	<ul style="list-style-type: none"> <li>Amy J. Berman, BSN Senior Program Officer, John A. Hartford Foundation</li> </ul>
0213	Proportion of patients who died from cancer admitted to the ICU in the last 30 days of life	American Society of Clinical Oncology	<ul style="list-style-type: none"> <li>Amy J. Berman, BSN Senior Program Officer, John A. Hartford Foundation</li> </ul>
0211	Proportion of patients who died from cancer with more than one emergency department visit in the last 30 days of life	American Society of Clinical Oncology	<ul style="list-style-type: none"> <li>Amy J. Berman, BSN Senior Program Officer, John A. Hartford Foundation</li> </ul>
0210	Proportion of patients who died from cancer receiving chemotherapy in the last 14 days of life	American Society of Clinical Oncology	<ul style="list-style-type: none"> <li>Amy J. Berman, BSN Senior Program Officer, John A. Hartford Foundation</li> </ul>